,docId,isValid,passage,passage_id,e1,e2
0,AIMed.d3,False,"Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).",AIMed.d3.s30,beta-galactosidase,senescence-associated beta-galactosidase
1,AIMed.d3,False,"Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).",AIMed.d3.s30,beta-galactosidase,SA-beta-gal
2,AIMed.d3,False,"Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).",AIMed.d3.s30,senescence-associated beta-galactosidase,SA-beta-gal
3,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,p16,INK4a
4,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,p16,p57
5,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,p16,KIP2
6,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,p16,p16
7,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,INK4a,p57
8,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,INK4a,KIP2
9,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,INK4a,p16
10,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,p57,KIP2
11,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,p57,p16
12,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31,KIP2,p16
13,AIMed.d3,False,"The induced expression of p57, similar to p16, produces a senescent-like phenotype.",AIMed.d3.s32,p57,p16
14,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,pRB,cyclin D
15,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,pRB,p19
16,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,pRB,INK4d
17,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,pRB,p27
18,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,pRB,KIP1
19,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,cyclin D,p19
20,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,cyclin D,INK4d
21,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,cyclin D,p27
22,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,cyclin D,KIP1
23,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,p19,INK4d
24,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,p19,p27
25,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,p19,KIP1
26,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,INK4d,p27
27,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,INK4d,KIP1
28,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33,p27,KIP1
29,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p53,p21
30,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p53,CIP1
31,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p53,p15
32,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p53,INK4b
33,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p21,CIP1
34,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p21,p15
35,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p21,INK4b
36,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,CIP1,p15
37,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,CIP1,INK4b
38,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34,p15,INK4b
39,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,p21
40,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,CIP1
41,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,p15
42,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,INK4b
43,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,p16
44,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,INK4a
45,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,p57
46,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p53,KIP2
47,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p21,CIP1
48,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p21,p15
49,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p21,INK4b
50,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p21,p16
51,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p21,INK4a
52,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p21,p57
53,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p21,KIP2
54,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,CIP1,p15
55,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,CIP1,INK4b
56,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,CIP1,p16
57,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,CIP1,INK4a
58,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,CIP1,p57
59,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,CIP1,KIP2
60,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p15,INK4b
61,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p15,p16
62,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p15,INK4a
63,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p15,p57
64,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p15,KIP2
65,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,INK4b,p16
66,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,INK4b,INK4a
67,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,INK4b,p57
68,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,INK4b,KIP2
69,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p16,INK4a
70,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p16,p57
71,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p16,KIP2
72,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,INK4a,p57
73,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,INK4a,KIP2
74,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35,p57,KIP2
75,AIMed.d4,False,Positive inotropic responses mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae.,AIMed.d4.s37,ET(A),ET(B)
76,AIMed.d4,False,The aim of the present study was to determine possible inotropic effects mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae from the right atrium and the left ventricle.,AIMed.d4.s38,ET(A),ET(B)
77,AIMed.d4,False,Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.,AIMed.d4.s40,Endothelin-1,ET-1
78,AIMed.d4,False,Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.,AIMed.d4.s40,Endothelin-1,ET-3
79,AIMed.d4,False,Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.,AIMed.d4.s40,ET-1,ET-3
80,AIMed.d4,False,ET-1 was significantly more potent than ET-3 in both atrial (P < 0.001) and ventricular (P < 0.05) trabeculae.,AIMed.d4.s41,ET-1,ET-3
81,AIMed.d4,False,"Preincubation with the ET(A) receptor antagonist FR139317 (1 microM) decreased significantly (P < 0.005) the potency of ET- I in both atrial and ventricular trabeculae, without any significant changes in Emax (maximum effect obtained with an agonist).",AIMed.d4.s42,ET(A) receptor,ET- I
82,AIMed.d4,False,"The ET(B) receptor agonist IRL 1620 had a positive inotropic effect only in some trabeculae, and the ET(B) receptor antagonist BQ 788 (1 microM) almost completely blocked this effect.",AIMed.d4.s43,ET(B) receptor,ET(B) receptor
83,AIMed.d4,False,These results suggest that both ET(A) and ET(B) receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart.,AIMed.d4.s44,ET(A),ET(B)
84,AIMed.d6,False,Apoptotic proteins. p53 and c-myc related pathways.,AIMed.d6.s50,p53,c-myc
85,AIMed.d6,False,c-Myc and p53 are two proteins that have critical roles in the regulation of apoptosis and the cell cycle.,AIMed.d6.s51,c-Myc,p53
86,AIMed.d7,False,A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum.,AIMed.d7.s53,E-cadherin,stromelysin-3
87,AIMed.d7,False,The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.,AIMed.d7.s56,E-cadherin,stromelysin-3
88,AIMed.d7,False,The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.,AIMed.d7.s56,E-cadherin,ST-3
89,AIMed.d7,False,The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.,AIMed.d7.s56,stromelysin-3,ST-3
90,AIMed.d7,False,"The rates of extensive ST-3 expression and decreased E-cadherin expression were significantly higher in the de novo group (P=0.014 and 0.005, respectively).",AIMed.d7.s57,ST-3,E-cadherin
91,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88,ErbB-1,ErbB-2
92,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88,ErbB-1,ErbB-3
93,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88,ErbB-1,ErbB-4
94,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88,ErbB-2,ErbB-3
95,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88,ErbB-2,ErbB-4
96,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88,ErbB-3,ErbB-4
97,AIMed.d11,False,"RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that ErbB-1 and ErbB-3 were also significant predictors.",AIMed.d11.s90,ErbB-1,ErbB-3
98,AIMed.d13,False,"We performed cell-free in vitro infection of primary bone marrow derived CD34+ cells using semi-purified HHV8 and a mature IL-2 dependent T cell line, KIT 225, using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV-1.",AIMed.d13.s109,CD34,IL-2
99,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112,interferon regulatory factor 4,IRF4
100,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112,interferon regulatory factor 4,cyclin B2
101,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112,interferon regulatory factor 4,pim 2
102,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112,IRF4,cyclin B2
103,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112,IRF4,pim 2
104,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112,cyclin B2,pim 2
105,AIMed.d19,False,"Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.",AIMed.d19.s162,natural resistance-associated protein,NRAMP1
106,AIMed.d19,False,"Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.",AIMed.d19.s162,natural resistance-associated protein,vitamin D receptor
107,AIMed.d19,False,"Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.",AIMed.d19.s162,NRAMP1,vitamin D receptor
108,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176,protein kinase C,PKC
109,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176,protein kinase C,"tyrosine kinase, phosphatidylinositol 3-kinase"
110,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176,protein kinase C,P13-K
111,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176,PKC,"tyrosine kinase, phosphatidylinositol 3-kinase"
112,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176,PKC,P13-K
113,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176,"tyrosine kinase, phosphatidylinositol 3-kinase",P13-K
114,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,collagenase
115,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,elastin
116,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,hyaluronic acid synthase 2
117,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,hyaluronidase
118,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,fibronectin
119,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,cd44
120,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,fibromodulin
121,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,procollagen I,decorin
122,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,collagenase,elastin
123,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,collagenase,hyaluronic acid synthase 2
124,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,collagenase,hyaluronidase
125,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,collagenase,fibronectin
126,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,collagenase,cd44
127,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,collagenase,fibromodulin
128,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,collagenase,decorin
129,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,elastin,hyaluronic acid synthase 2
130,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,elastin,hyaluronidase
131,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,elastin,fibronectin
132,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,elastin,cd44
133,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,elastin,fibromodulin
134,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,elastin,decorin
135,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronic acid synthase 2,hyaluronidase
136,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronic acid synthase 2,fibronectin
137,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronic acid synthase 2,cd44
138,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronic acid synthase 2,fibromodulin
139,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronic acid synthase 2,decorin
140,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronidase,fibronectin
141,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronidase,cd44
142,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronidase,fibromodulin
143,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,hyaluronidase,decorin
144,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,fibronectin,cd44
145,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,fibronectin,fibromodulin
146,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,fibronectin,decorin
147,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,cd44,fibromodulin
148,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,cd44,decorin
149,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200,fibromodulin,decorin
150,AIMed.d28,True,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR,hGITRL
151,AIMed.d28,True,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR ligand,hGITR
152,AIMed.d28,True,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,hGITRL,hGITR
153,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR,GITR ligand
154,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR,hGITR
155,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR,mGITR
156,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR,glucocorticoid-induced TNFR-related (mGITR) protein
157,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR ligand,hGITRL
158,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR ligand,mGITR
159,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,GITR ligand,glucocorticoid-induced TNFR-related (mGITR) protein
160,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,hGITRL,mGITR
161,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,hGITRL,glucocorticoid-induced TNFR-related (mGITR) protein
162,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,hGITR,mGITR
163,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,hGITR,glucocorticoid-induced TNFR-related (mGITR) protein
164,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234,mGITR,glucocorticoid-induced TNFR-related (mGITR) protein
165,AIMed.d28,False,"The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].",AIMed.d28.s235,hGITRL,Fas
166,AIMed.d28,False,"The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].",AIMed.d28.s235,hGITRL,CD95 ligand
167,AIMed.d28,False,"The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].",AIMed.d28.s235,Fas,CD95 ligand
168,AIMed.d28,False,"We found hGITRL mRNA in several peripheral tissues, and detected hGITRL protein on cultured vascular endothelial cells.",AIMed.d28.s237,hGITRL,hGITRL
169,AIMed.d28,False,"The levels of hGITR mRNA in tissues were generally low; in peripheral blood T cells, however, antigen-receptor stimulation led to a substantial induction of hGITR transcripts.",AIMed.d28.s238,hGITR,hGITR
170,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITRL,hGITR
171,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITRL,NF-kappaB
172,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITRL,TNFR-associated factor 2
173,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITRL,TRAF2
174,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITRL,NF-kappaB
175,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITRL,NF-kappaB-inducing kinase
176,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITRL,NIK
177,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITR,NF-kappaB
178,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITR,TNFR-associated factor 2
179,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITR,TRAF2
180,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITR,NF-kappaB
181,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITR,NF-kappaB-inducing kinase
182,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,hGITR,NIK
183,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB,TNFR-associated factor 2
184,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB,TRAF2
185,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB,NF-kappaB
186,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB,NF-kappaB-inducing kinase
187,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB,NIK
188,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,TNFR-associated factor 2,TRAF2
189,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,TNFR-associated factor 2,NF-kappaB
190,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,TNFR-associated factor 2,NF-kappaB-inducing kinase
191,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,TNFR-associated factor 2,NIK
192,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,TRAF2,NF-kappaB
193,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,TRAF2,NF-kappaB-inducing kinase
194,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,TRAF2,NIK
195,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB,NF-kappaB-inducing kinase
196,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB,NIK
197,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239,NF-kappaB-inducing kinase,NIK
198,AIMed.d28,False,Cotransfection of hGITRL and hGITR in Jurkat T leukemia cells inhibited antigen-receptor-induced cell death.,AIMed.d28.s240,hGITRL,hGITR
199,AIMed.d28,False,"Thus, hGITRL and hGITR may modulate T lymphocyte survival in peripheral tissues.",AIMed.d28.s241,hGITRL,hGITR
200,AIMed.d31,False,A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.,AIMed.d31.s256,TR6,LIGHT
201,AIMed.d31,False,TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.,AIMed.d31.s257,TR6,decoy receptor 3
202,AIMed.d31,False,TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.,AIMed.d31.s257,TR6,DcR3
203,AIMed.d31,False,TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.,AIMed.d31.s257,decoy receptor 3,DcR3
204,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,TR6,LIGHT
205,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,TR6,herpes virus entry mediator (HVEM)-L
206,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,TR6,Fas ligand
207,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,TR6,FasL
208,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,TR6,CD95L
209,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,TR6,HVEM
210,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,LIGHT,HVEM
211,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,LIGHT,herpes virus entry mediator (HVEM)-L
212,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,LIGHT,Fas ligand
213,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,LIGHT,FasL
214,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,LIGHT,CD95L
215,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,HVEM,herpes virus entry mediator (HVEM)-L
216,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,HVEM,Fas ligand
217,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,HVEM,FasL
218,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,HVEM,CD95L
219,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,herpes virus entry mediator (HVEM)-L,Fas ligand
220,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,herpes virus entry mediator (HVEM)-L,FasL
221,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,herpes virus entry mediator (HVEM)-L,CD95L
222,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,Fas ligand,FasL
223,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,Fas ligand,CD95L
224,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262,FasL,CD95L
225,AIMed.d31,False,TR6 inhibited LIGHT-induced cytotoxicity in HT29 cells.,AIMed.d31.s264,TR6,LIGHT
226,AIMed.d31,True,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,lymphotoxin beta,LTbetaR
227,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,LIGHT,lymphotoxin beta
228,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,LIGHT,lymphotoxin beta receptor
229,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,LIGHT,LTbetaR
230,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,LIGHT,HVEM
231,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,LIGHT,TR2
232,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,lymphotoxin beta,lymphotoxin beta receptor
233,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,lymphotoxin beta,HVEM
234,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,lymphotoxin beta,TR2
235,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,lymphotoxin beta receptor,LTbetaR
236,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,lymphotoxin beta receptor,HVEM
237,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,lymphotoxin beta receptor,TR2
238,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,LTbetaR,HVEM
239,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,LTbetaR,TR2
240,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265,HVEM,TR2
241,AIMed.d31,True,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,LIGHT,HVEM
242,AIMed.d31,True,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,LIGHT,TR2
243,AIMed.d31,True,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,LIGHT,LTbetaR
244,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,TR6,LIGHT
245,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,TR6,HVEM
246,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,TR6,TR2
247,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,TR6,LTbetaR
248,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,TR6,LIGHT
249,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,LIGHT,LIGHT
250,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,HVEM,TR2
251,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,HVEM,LTbetaR
252,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,HVEM,LIGHT
253,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,TR2,LTbetaR
254,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,TR2,LIGHT
255,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266,LTbetaR,LIGHT
256,AIMed.d31,False,"Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.",AIMed.d31.s267,TR6,FasL
257,AIMed.d31,False,"Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.",AIMed.d31.s267,TR6,LIGHT
258,AIMed.d31,False,"Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.",AIMed.d31.s267,FasL,LIGHT
259,AIMed.d34,False,Presenilin 1 (PS1) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.,AIMed.d34.s285,Presenilin 1,PS1
260,AIMed.d34,True,"We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.",AIMed.d34.s288,PS1,Rab11
261,AIMed.d34,True,"We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.",AIMed.d34.s288,PS2,Rab11
262,AIMed.d34,False,"We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.",AIMed.d34.s288,PS1,PS2
263,AIMed.d34,True,"Interaction domains were mapped to codons 374-400 for PS1 and to codons 106-179 for Rab11, a region including the fourth GTP-binding domain.",AIMed.d34.s289,PS1,Rab11
264,AIMed.d38,True,Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3.,AIMed.d38.s320,Eotaxin-3,CC chemokine receptor 3
265,AIMed.d38,False,"Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).",AIMed.d38.s321,myeloid progenitor inhibitory factor 2,MPIF-2
266,AIMed.d38,False,"Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).",AIMed.d38.s321,myeloid progenitor inhibitory factor 2,eotaxin-2
267,AIMed.d38,False,"Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).",AIMed.d38.s321,MPIF-2,eotaxin-2
268,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323,MPIF-2,eotaxin-2
269,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323,MPIF-2,SCYA24
270,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323,MPIF-2,eotaxin-3
271,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323,eotaxin-2,SCYA24
272,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323,eotaxin-2,eotaxin-3
273,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323,SCYA24,eotaxin-3
274,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,MPIF-2,eotaxin-2
275,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,MPIF-2,SCYA24
276,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,MPIF-2,eotaxin-3
277,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,MPIF-2,SCYA26
278,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,eotaxin-2,SCYA24
279,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,eotaxin-2,eotaxin-3
280,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,eotaxin-2,SCYA26
281,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,SCYA24,eotaxin-3
282,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,SCYA24,SCYA26
283,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324,eotaxin-3,SCYA26
284,AIMed.d38,False,Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.,AIMed.d38.s327,Eotaxin-3,CC chemokine receptor 3
285,AIMed.d38,False,Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.,AIMed.d38.s327,Eotaxin-3,CCR3
286,AIMed.d38,False,Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.,AIMed.d38.s327,CC chemokine receptor 3,CCR3
287,AIMed.d38,True,Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.,AIMed.d38.s328,Eotaxin-3,CCR3
288,AIMed.d38,True,Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.,AIMed.d38.s328,I-eotaxin,CCR3
289,AIMed.d38,False,Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.,AIMed.d38.s328,Eotaxin-3,I-eotaxin
290,AIMed.d38,True,"Collectively, eotaxin-3 is yet another functional ligand for CCR3.",AIMed.d38.s330,eotaxin-3,CCR3
291,AIMed.d38,True,"The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.",AIMed.d38.s331,eotaxin-3,CCR3
292,AIMed.d38,True,"The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.",AIMed.d38.s331,CCR3,eotaxin
293,AIMed.d38,False,"The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.",AIMed.d38.s331,eotaxin-3,eotaxin
294,AIMed.d38,False,Identification of eotaxin-3 will further promote our understanding of the control of eosinophil trafficking and other CCR3-mediated biological phenomena.,AIMed.d38.s332,eotaxin-3,CCR3
295,AIMed.d45,True,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma SC1,IFN-gamma receptor alpha chain
296,AIMed.d45,True,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma SC1,IFN-gamma R alpha
297,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,interferon-gamma,IFN-gamma
298,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,interferon-gamma,IFN-gamma SC1
299,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,interferon-gamma,IFN-gamma
300,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,interferon-gamma,IFN-gamma receptor
301,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,interferon-gamma,IFN-gamma receptor alpha chain
302,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,interferon-gamma,IFN-gamma
303,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,interferon-gamma,IFN-gamma R alpha
304,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma SC1
305,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma
306,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma receptor
307,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma receptor alpha chain
308,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma
309,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma R alpha
310,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma SC1,IFN-gamma
311,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma SC1,IFN-gamma receptor
312,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma SC1,IFN-gamma
313,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma receptor
314,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma receptor alpha chain
315,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma
316,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma R alpha
317,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma receptor,IFN-gamma receptor alpha chain
318,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma receptor,IFN-gamma
319,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma receptor,IFN-gamma R alpha
320,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma receptor alpha chain,IFN-gamma
321,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma receptor alpha chain,IFN-gamma R alpha
322,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390,IFN-gamma,IFN-gamma R alpha
323,AIMed.d45,False,IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.,AIMed.d45.s391,IFN-gamma,IFN-gamma SC1
324,AIMed.d45,False,IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.,AIMed.d45.s391,IFN-gamma,IFN-gamma
325,AIMed.d45,False,IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.,AIMed.d45.s391,IFN-gamma SC1,IFN-gamma
326,AIMed.d45,True,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392,IFN-gamma SC1,IFN-gamma R alpha
327,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392,IFN-gamma,IFN-gamma SC1
328,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392,IFN-gamma,IFN-gamma
329,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392,IFN-gamma,IFN-gamma R alpha
330,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392,IFN-gamma SC1,IFN-gamma
331,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392,IFN-gamma,IFN-gamma R alpha
332,AIMed.d45,False,The crystal structure of IFN-gamma SC1 has been determined at 2.9 A resolution from crystals grown in 1.4 M citrate solutions at pH 7.6.,AIMed.d45.s393,IFN-gamma,IFN-gamma SC1
333,AIMed.d45,False,Comparison of the wild-type receptor-binding domain and the Asp111-containing domain of IFN-gamma SC1 show that they are structurally equivalent but have very different electrostatic surface potentials.,AIMed.d45.s394,IFN-gamma,IFN-gamma SC1
334,AIMed.d45,True,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma,IFN-gamma R alpha
335,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma SC1,IFN-gamma
336,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma SC1,IFN-gamma
337,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma SC1,IFN-gamma
338,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma SC1,IFN-gamma R alpha
339,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma,IFN-gamma
340,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma,IFN-gamma
341,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma,IFN-gamma R alpha
342,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma,IFN-gamma
343,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396,IFN-gamma,IFN-gamma R alpha
344,AIMed.d45,False,"Thus, IFN-gamma R alpha binding does not result in a large conformational change in the AB loop as previously suggested.",AIMed.d45.s397,IFN-gamma,IFN-gamma R alpha
345,AIMed.d45,False,The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.,AIMed.d45.s398,IFN-gamma,IFN-gamma SC1
346,AIMed.d45,False,The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.,AIMed.d45.s398,IFN-gamma,IFN-gamma
347,AIMed.d45,False,The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.,AIMed.d45.s398,IFN-gamma SC1,IFN-gamma
348,AIMed.d45,True,"Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.",AIMed.d45.s399,IFN-gamma R alpha,IFN-gamma SC1
349,AIMed.d45,False,"Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.",AIMed.d45.s399,IFN-gamma,IFN-gamma R alpha
350,AIMed.d45,False,"Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.",AIMed.d45.s399,IFN-gamma,IFN-gamma SC1
351,AIMed.d45,True,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma R alpha
352,AIMed.d45,True,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma R beta
353,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma
354,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma
355,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma R alpha
356,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma
357,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma R beta
358,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma R alpha,IFN-gamma
359,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma R alpha,IFN-gamma R beta
360,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400,IFN-gamma,IFN-gamma R beta
361,AIMed.d45,False,The current data are consistent with the main role of the IFN-gamma dimer being to decrease the dissociation constant of IFN-gamma for its cellular receptors.,AIMed.d45.s401,IFN-gamma,IFN-gamma
362,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CC chemokine liver-expressed chemokine,CCR1
363,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CC chemokine liver-expressed chemokine,CCR2
364,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CC chemokine liver-expressed chemokine,CCR5
365,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CCL16,CCR1
366,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CCL16,CCR2
367,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CCL16,CCR5
368,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CC chemokine liver-expressed chemokine,CCL16
369,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CCR1,CCR2
370,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CCR1,CCR5
371,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481,CCR2,CCR5
372,AIMed.d55,False,Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.,AIMed.d55.s482,Liver-expressed chemokine,LEC
373,AIMed.d55,False,Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.,AIMed.d55.s482,Liver-expressed chemokine,CCL16
374,AIMed.d55,False,Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.,AIMed.d55.s482,LEC,CCL16
375,AIMed.d55,True,"At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.",AIMed.d55.s484,LEC,CCR1
376,AIMed.d55,True,"At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.",AIMed.d55.s484,LEC,CCR2
377,AIMed.d55,False,"At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.",AIMed.d55.s484,CCR1,CCR2
378,AIMed.d55,True,"LEC also induced calcium mobilization, but marginal chemotaxis via CCR5.",AIMed.d55.s485,LEC,CCR5
379,AIMed.d55,True,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486,LEC,CCR1
380,AIMed.d55,True,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486,LEC,CCR2
381,AIMed.d55,True,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486,LEC,CCR5
382,AIMed.d55,False,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486,CCR1,CCR2
383,AIMed.d55,False,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486,CCR1,CCR5
384,AIMed.d55,False,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486,CCR2,CCR5
385,AIMed.d55,True,The binding of LEC to CCR8 was much less significant.,AIMed.d55.s487,LEC,CCR8
386,AIMed.d55,True,"In spite of its binding to CCR5, LEC was unable to inhibit infection of an R5-type HIV-1 to activated human peripheral blood mononuclear cells even at high concentrations.",AIMed.d55.s488,CCR5,LEC
387,AIMed.d55,True,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492,LEC,CCR1
388,AIMed.d55,True,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492,LEC,CCR2
389,AIMed.d55,True,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492,LEC,CCR5
390,AIMed.d55,False,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492,CCR1,CCR2
391,AIMed.d55,False,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492,CCR1,CCR5
392,AIMed.d55,False,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492,CCR2,CCR5
393,AIMed.d62,False,The crystal structure of the homodimeric BB isoform of human recombinant platelet-derived growth factor (PDGF-BB) has been determined by X-ray analysis to 3.0 A resolution.,AIMed.d62.s541,BB isoform of human recombinant platelet-derived growth factor,PDGF-BB
394,AIMed.d66,False,"Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.",AIMed.d66.s562,cyclin E,CDC2
395,AIMed.d66,True,"Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.",AIMed.d66.s564,Cyclin E,CDC28
396,AIMed.d66,True,"Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.",AIMed.d66.s564,Cyclin E,CDC28
397,AIMed.d66,False,"Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.",AIMed.d66.s564,CDC28,CDC28
398,AIMed.d66,False,Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation.,AIMed.d66.s565,cyclin E,cdc28
399,AIMed.d66,False,"One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.",AIMed.d66.s566,CDC2,CDC2-HS
400,AIMed.d66,False,"One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.",AIMed.d66.s566,CDC2,CDK2
401,AIMed.d66,False,"One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.",AIMed.d66.s566,CDC2-HS,CDK2
402,AIMed.d66,True,"Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.",AIMed.d66.s567,Cyclin E,CDC2
403,AIMed.d66,False,"Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.",AIMed.d66.s567,Cyclin E,cyclin E
404,AIMed.d66,False,"Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.",AIMed.d66.s567,CDC2,cyclin E
405,AIMed.d66,True,"The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.",AIMed.d66.s568,cyclin E,CDC2
406,AIMed.d66,True,"The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.",AIMed.d66.s568,cyclin E,CDK2
407,AIMed.d66,False,"The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.",AIMed.d66.s568,CDC2,CDK2
408,AIMed.d72,False,A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product.,AIMed.d72.s609,SV40 T antigen,retinoblastoma
409,AIMed.d72,False,"Tumour-suppressor genes, such as the human retinoblastoma susceptibility gene (Rb), are widely recognized as being vital in the control of cell growth and tumour formation.",AIMed.d72.s610,retinoblastoma susceptibility gene,Rb
410,AIMed.d72,False,"How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.",AIMed.d72.s612,Rb,Rb
411,AIMed.d72,False,"How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.",AIMed.d72.s612,Rb,Rb
412,AIMed.d72,False,"How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.",AIMed.d72.s612,Rb,Rb
413,AIMed.d72,False,"We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).",AIMed.d72.s614,Rb,Rb-associated protein
414,AIMed.d72,False,"We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).",AIMed.d72.s614,Rb,RbAP46
415,AIMed.d72,False,"We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).",AIMed.d72.s614,Rb-associated protein,RbAP46
416,AIMed.d72,True,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,Rb
417,AIMed.d72,True,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,simian virus 40 T antigen,Rb
418,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,simian virus 40 T antigen
419,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,Rb
420,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,RbAP46
421,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,RbAP46
422,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,Rb
423,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,simian virus 40 T antigen,Rb
424,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,simian virus 40 T antigen,RbAP46
425,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,simian virus 40 T antigen,RbAP46
426,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,simian virus 40 T antigen,Rb
427,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,Rb,Rb
428,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,Rb,RbAP46
429,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,Rb,RbAP46
430,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,Rb,Rb
431,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,Rb,RbAP46
432,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,Rb,RbAP46
433,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,Rb,Rb
434,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,RbAP46
435,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,Rb
436,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615,RbAP46,Rb
437,AIMed.d72,True,The apparent targeting of the RbAP46-Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.,AIMed.d72.s616,RbAP46,Rb
438,AIMed.d84,True,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,insulin receptor substrate-1,insulin-like growth factor-I (IGF-I) receptor
439,AIMed.d84,True,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,IRS-1,insulin-like growth factor-I (IGF-I) receptor
440,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,SHC,insulin receptor substrate-1
441,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,SHC,IRS-1
442,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,SHC,insulin-like growth factor-I
443,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,SHC,IGF-I
444,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,SHC,insulin-like growth factor-I (IGF-I) receptor
445,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,insulin receptor substrate-1,IRS-1
446,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,insulin receptor substrate-1,insulin-like growth factor-I
447,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,insulin receptor substrate-1,IGF-I
448,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,IRS-1,insulin-like growth factor-I
449,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,IRS-1,IGF-I
450,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,insulin-like growth factor-I,IGF-I
451,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,insulin-like growth factor-I,insulin-like growth factor-I (IGF-I) receptor
452,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711,IGF-I,insulin-like growth factor-I (IGF-I) receptor
453,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I receptor,p52Shc
454,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I receptor,insulin receptor substrate-1
455,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I receptor,IRS-1
456,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IGF-IR,p52Shc
457,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IGF-IR,insulin receptor substrate-1
458,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IGF-IR,IRS-1
459,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor,p52Shc
460,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor,insulin receptor substrate-1
461,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor,IRS-1
462,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IR,p52Shc
463,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IR,insulin receptor substrate-1
464,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IR,IRS-1
465,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,insulin-like growth factor-I receptor
466,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,IGF-IR
467,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,insulin receptor
468,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,IR
469,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,p52Shc
470,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,insulin receptor
471,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,insulin receptor substrate-1
472,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I,IRS-1
473,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I receptor,IGF-IR
474,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I receptor,insulin receptor
475,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I receptor,IR
476,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin-like growth factor-I receptor,insulin receptor
477,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IGF-IR,insulin receptor
478,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IGF-IR,IR
479,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IGF-IR,insulin receptor
480,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor,IR
481,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor,insulin receptor
482,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,IR,insulin receptor
483,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,p52Shc,insulin receptor
484,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,p52Shc,insulin receptor substrate-1
485,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,p52Shc,IRS-1
486,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor,insulin receptor substrate-1
487,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor,IRS-1
488,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712,insulin receptor substrate-1,IRS-1
489,AIMed.d84,False,We also mapped the specific domains of the IGF-IR and p52Shc participating in these interactions.,AIMed.d84.s713,IGF-IR,p52Shc
490,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,p52Shc
491,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IRS-1
492,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
493,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
494,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
495,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IR
496,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
497,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,p52Shc
498,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IRS-1
499,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IGF-IR
500,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,p52Shc
501,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IRS-1
502,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IGF-IR
503,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,p52Shc
504,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IR
505,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IGF-IR
506,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IRS-1
507,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,p52Shc
508,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IRS-1
509,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
510,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,p52Shc
511,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IRS-1
512,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
513,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,p52Shc
514,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IR
515,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
516,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,p52Shc
517,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IRS-1
518,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
519,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,p52Shc
520,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IRS-1
521,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
522,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,p52Shc
523,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IR
524,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
525,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IRS-1
526,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,p52Shc
527,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IRS-1
528,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
529,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,p52Shc
530,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IR
531,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
532,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,p52Shc
533,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IRS-1
534,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
535,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,p52Shc
536,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IR
537,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
538,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,p52Shc
539,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IRS-1
540,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IGF-IR
541,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,p52Shc
542,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IR
543,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IGF-IR
544,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IRS-1
545,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
546,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,p52Shc
547,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IR
548,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,p52Shc,IGF-IR
549,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,p52Shc
550,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IR
551,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IRS-1,IGF-IR
552,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,p52Shc
553,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IR
554,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IGF-IR,IGF-IR
555,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714,IR,IGF-IR
556,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IGF-IR,p52Shc
557,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IGF-IR,IRS-1
558,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IR,p52Shc
559,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IR,IRS-1
560,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IRS-1,IGF-IR
561,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IGF-IR,p52Shc
562,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IGF-IR,IR
563,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IGF-IR,IRS-1
564,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IGF-IR,IGF-IR
565,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IGF-IR,p52Shc
566,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IR,IRS-1
567,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IR,IGF-IR
568,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IR,p52Shc
569,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,p52Shc,IRS-1
570,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,p52Shc,IRS-1
571,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,p52Shc,IGF-IR
572,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,p52Shc,p52Shc
573,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IRS-1,IRS-1
574,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IRS-1,IGF-IR
575,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IRS-1,p52Shc
576,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715,IRS-1,p52Shc
577,AIMed.d84,False,"Finally, our data highlight the crucial role of the juxtamembrane domain in signaling by both the IR and the IGF-IR.",AIMed.d84.s716,IR,IGF-IR
578,AIMed.d86,False,"For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.",AIMed.d86.s728,Myc,Max
579,AIMed.d86,False,"For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.",AIMed.d86.s728,Myc,Mxi1
580,AIMed.d86,False,"For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.",AIMed.d86.s728,Max,Mxi1
581,AIMed.d88,True,"Interaction of the protein nucleobindin with G alpha i2, as revealed by the yeast two-hybrid system.",AIMed.d88.s742,nucleobindin,G alpha i2
582,AIMed.d88,True,The specificity of intehraction between G alpha i2 and nucleobindin was confirmed by an in vitro binding assay using recombinant proteins.,AIMed.d88.s749,G alpha i2,nucleobindin
583,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750,G alpha i2,nucleobindin
584,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750,G alpha i2,G alpha i2
585,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750,G alpha i2,G alpha i2
586,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750,nucleobindin,G alpha i2
587,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750,nucleobindin,G alpha i2
588,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750,G alpha i2,G alpha i2
589,AIMed.d106,True,Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation.,AIMed.d106.s893,Raf1,Cdc25 phosphatase
590,AIMed.d106,False,The Ras and Raf1 proto-oncogenes transduce extracellular signals that promote cell growth.,AIMed.d106.s894,Ras,Raf1
591,AIMed.d106,True,We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes.,AIMed.d106.s896,Cdc25 phosphatase,raf1
592,AIMed.d106,True,"Furthermore, Cdc25 phosphatase can be activated in vitro in a Raf1-dependent manner.",AIMed.d106.s897,Cdc25 phosphatase,Raf1
593,AIMed.d106,False,We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.,AIMed.d106.s898,Ras,Raf1
594,AIMed.d106,False,We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.,AIMed.d106.s898,Ras,Cdc25
595,AIMed.d106,False,We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.,AIMed.d106.s898,Raf1,Cdc25
596,AIMed.d107,True,A direct interaction between G-protein beta gamma subunits and the Raf-1 protein kinase.,AIMed.d107.s899,G-protein beta gamma,Raf-1 protein kinase
597,AIMed.d107,False,Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.,AIMed.d107.s900,Raf-1,Ras
598,AIMed.d107,False,Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.,AIMed.d107.s900,Raf-1,mitogen-activated protein kinase
599,AIMed.d107,False,Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.,AIMed.d107.s900,Ras,mitogen-activated protein kinase
600,AIMed.d107,True,"Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate Raf-1, we isolated a clone encoding the carboxyl-terminal half of the G beta 2 subunit of heterotrimeric G-proteins.",AIMed.d107.s901,Raf-1,G beta 2 subunit
601,AIMed.d107,True,"In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).",AIMed.d107.s902,G beta gamma,Raf-1
602,AIMed.d107,True,"In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).",AIMed.d107.s902,G beta gamma,Raf/330
603,AIMed.d107,False,"In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).",AIMed.d107.s902,Raf-1,Raf/330
604,AIMed.d107,False,Binding assays with truncation mutants of GST-Raf indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with G beta gamma.,AIMed.d107.s903,Raf,G beta gamma
605,AIMed.d107,True,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,G beta gamma,Raf/330
606,AIMed.d107,True,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,Raf-1,Ras
607,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta-adrenergic receptor kinase,beta ARK
608,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta-adrenergic receptor kinase,G beta gamma
609,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta-adrenergic receptor kinase,Raf/330
610,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta-adrenergic receptor kinase,Raf-1
611,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta-adrenergic receptor kinase,Ras
612,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta ARK,G beta gamma
613,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta ARK,Raf/330
614,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta ARK,Raf-1
615,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,beta ARK,Ras
616,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,G beta gamma,Raf-1
617,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,G beta gamma,Ras
618,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,Raf/330,Raf-1
619,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904,Raf/330,Ras
620,AIMed.d107,True,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905,Raf/330,G beta gamma
621,AIMed.d107,True,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905,G beta gamma,beta ARK
622,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905,Raf/330,G beta gamma
623,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905,Raf/330,beta ARK
624,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905,G beta gamma,G beta gamma
625,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905,G beta gamma,beta ARK
626,AIMed.d107,False,"The formation of native heterotrimeric G alpha beta gamma complexes, as measured by pertussis toxin ADP-ribosylation of G alpha, could be disrupted by increasing amounts of Raf/330, with an EC50 of approximately 200 nM, in close agreement with the estimated binding affinity.",AIMed.d107.s906,G alpha beta gamma,Raf/330
627,AIMed.d107,True,In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.,AIMed.d107.s907,Raf-1,G beta gamma
628,AIMed.d107,False,In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.,AIMed.d107.s907,Raf-1,G beta 2
629,AIMed.d107,False,In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.,AIMed.d107.s907,G beta gamma,G beta 2
630,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930,RII beta,cAMP-dependent protein kinase II beta
631,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930,RII beta,RII beta
632,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930,RII beta,RII beta
633,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930,cAMP-dependent protein kinase II beta,RII beta
634,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930,cAMP-dependent protein kinase II beta,RII beta
635,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930,RII beta,RII beta
636,AIMed.d111,False,In neurons cAMP-dependent protein kinase II beta (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).,AIMed.d111.s931,cAMP-dependent protein kinase II beta,PKAII beta
637,AIMed.d111,False,In neurons cAMP-dependent protein kinase II beta (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).,AIMed.d111.s931,cAMP-dependent protein kinase II beta,RII beta
638,AIMed.d111,False,In neurons cAMP-dependent protein kinase II beta (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).,AIMed.d111.s931,PKAII beta,RII beta
639,AIMed.d111,True,The prototypic neuronal anchor protein AKAP75 has a COOH-terminal 22-residue RII beta binding (tethering) site.,AIMed.d111.s932,AKAP75,RII beta
640,AIMed.d111,True,"Mutagenesis, recombinant protein expression, and physicochemical characterization were used to investigate the structural basis for the homodimerization and AKAP75 binding activities of RII beta.",AIMed.d111.s934,AKAP75,RII beta
641,AIMed.d111,False,Substitution of Ala for Leu13 or Phe36 generates monomeric RII beta subunits that cannot bind AKAP75.,AIMed.d111.s936,RII beta,AKAP75
642,AIMed.d111,False,The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type RII beta dimers.,AIMed.d111.s937,RII beta,PKAII beta
643,AIMed.d111,False,The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type RII beta dimers.,AIMed.d111.s937,RII beta,RII beta
644,AIMed.d111,False,The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type RII beta dimers.,AIMed.d111.s937,PKAII beta,RII beta
645,AIMed.d111,True,"Evidently, large hydrophobic side chains of Leu13 and Phe36 play pivotal roles in stabilizing RII beta-RII beta interactions.",AIMed.d111.s939,RII beta,RII beta
646,AIMed.d111,False,A secondary consequence of destabilizing RII beta dimers is the loss of intracellular targeting/anchoring capacity because monomers fail to bind AKAP75.,AIMed.d111.s940,RII beta,AKAP75
647,AIMed.d111,True,Other NH2-terminal residues directly modulate the affinity of RII beta dimers for the AKAP75 tethering site.,AIMed.d111.s941,RII beta,AKAP75
648,AIMed.d111,True,Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4% as avidly as wild-type RII beta.,AIMed.d111.s942,RII beta,AKAP75
649,AIMed.d111,False,Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4% as avidly as wild-type RII beta.,AIMed.d111.s942,RII beta,RII beta
650,AIMed.d111,False,Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4% as avidly as wild-type RII beta.,AIMed.d111.s942,AKAP75,RII beta
651,AIMed.d133,True,JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.,AIMed.d133.s1132,JNK1,c-Jun
652,AIMed.d133,False,JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.,AIMed.d133.s1132,JNK1,Ha-Ras
653,AIMed.d133,False,JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.,AIMed.d133.s1132,Ha-Ras,c-Jun
654,AIMed.d133,False,The ultraviolet (UV) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by AP-1 and NF-kappa B.,AIMed.d133.s1133,AP-1,NF-kappa B
655,AIMed.d133,False,"The effect on AP-1 transcriptional activity results, in part, from enhanced phosphorylation of the c-Jun NH2-terminal activation domain.",AIMed.d133.s1134,AP-1,c-Jun
656,AIMed.d133,False,"Here, we describe the molecular cloning and characterization of JNK1, a distant relative of the MAP kinase group that is activated by dual phosphorylation at Thr and Tyr during the UV response.",AIMed.d133.s1135,JNK1,MAP kinase
657,AIMed.d133,True,"Significantly, Ha-Ras partially activates JNK1 and potentiates the activation caused by UV.",AIMed.d133.s1136,Ha-Ras,JNK1
658,AIMed.d133,True,JNK1 binds to the c-Jun transactivation domain and phosphorylates it on Ser-63 and Ser-73.,AIMed.d133.s1137,JNK1,c-Jun
659,AIMed.d134,True,B61 is a ligand for the ECK receptor protein-tyrosine kinase.,AIMed.d134.s1140,B61,ECK receptor protein-tyrosine kinase
660,AIMed.d134,False,B61 is a ligand for the ECK receptor protein-tyrosine kinase.,AIMed.d134.s1140,B61,ECK
661,AIMed.d134,False,B61 is a ligand for the ECK receptor protein-tyrosine kinase.,AIMed.d134.s1140,ECK,ECK receptor protein-tyrosine kinase
662,AIMed.d134,False,A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.,AIMed.d134.s1141,ECK,ECK receptor protein-tyrosine kinase
663,AIMed.d134,False,A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.,AIMed.d134.s1141,ECK,ECK
664,AIMed.d134,False,A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.,AIMed.d134.s1141,ECK receptor protein-tyrosine kinase,ECK
665,AIMed.d134,False,"Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of B61, a protein previously identified as the product of an early response gene induced by tumour necrosis factor-alpha.",AIMed.d134.s1143,B61,tumour necrosis factor-alpha
666,AIMed.d134,True,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144,B61,ECK
667,AIMed.d134,True,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144,B61,ECK
668,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144,B61,B61
669,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144,B61,ECK
670,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144,ECK,B61
671,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144,ECK,ECK
672,AIMed.d134,False,"ECK is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH, and we suggest that ligands for other members of this family will be related to B61, and can be isolated in the same way.",AIMed.d134.s1145,ECK,B61
673,AIMed.d140,True,"Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2.",AIMed.d140.s1180,Cdi1,Cdk2
674,AIMed.d140,False,"We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human cyclin-dependent kinase interactor 1 (Cdi1).",AIMed.d140.s1181,cyclin-dependent kinase interactor 1,Cdi1
675,AIMed.d140,True,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdi1,Cdc2
676,AIMed.d140,True,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdi1,Cdk2
677,AIMed.d140,True,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdi1,Cdk3
678,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdi1,Cdk4
679,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdc2,Cdk2
680,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdc2,Cdk3
681,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdc2,Cdk4
682,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdk2,Cdk3
683,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdk2,Cdk4
684,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182,Cdk3,Cdk4
685,AIMed.d140,True,"In HeLa cells, Cdi1 is expressed at the G1 to S transition, and the protein forms stable complexes with Cdk2.",AIMed.d140.s1183,Cdi1,Cdk2
686,AIMed.d140,False,Overexpression of wild-type Cdi1 delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on Cdi1 phosphatase activity.,AIMed.d140.s1186,Cdi1,Cdi1
687,AIMed.d149,True,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262,GRB2,IRS1
688,AIMed.d149,True,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262,GRB2,Shc
689,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262,GRB2,ras
690,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262,IRS1,Shc
691,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262,IRS1,ras
692,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262,Shc,ras
693,AIMed.d149,False,"GRB2, a small protein comprising one SH2 domain and two SH3 domains, represents the human homologue of the Caenorhabditis elegans protein, sem-5.",AIMed.d149.s1263,GRB2,sem-5
694,AIMed.d149,False,Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.,AIMed.d149.s1264,GRB2,sem-5
695,AIMed.d149,False,Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.,AIMed.d149.s1264,GRB2,p21ras
696,AIMed.d149,False,Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.,AIMed.d149.s1264,sem-5,p21ras
697,AIMed.d149,False,"In this report we show that in response to insulin, GRB2 forms a stable complex with two tyrosine-phosphorylated proteins.",AIMed.d149.s1265,insulin,GRB2
698,AIMed.d149,False,"One protein is the major insulin receptor substrate IRS-1 and the second is the SH2 domain-containing oncogenic protein, Shc.",AIMed.d149.s1266,IRS-1,Shc
699,AIMed.d149,True,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,GRB2,IRS-1
700,AIMed.d149,True,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,GRB2,Shc
701,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,GRB2,insulin receptor
702,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,GRB2,GRB2
703,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,GRB2,IRS-1
704,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,GRB2,Shc
705,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,insulin receptor,GRB2
706,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,insulin receptor,IRS-1
707,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,insulin receptor,Shc
708,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267,IRS-1,Shc
709,AIMed.d149,True,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,GRB2,IRS-1
710,AIMed.d149,True,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,GRB2,Shc
711,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,GRB2,insulin
712,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,GRB2,GRB2
713,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,IRS-1,Shc
714,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,IRS-1,insulin
715,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,IRS-1,GRB2
716,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,Shc,insulin
717,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,Shc,GRB2
718,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268,insulin,GRB2
719,AIMed.d149,True,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269,IRS-1,GRB2
720,AIMed.d149,True,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269,EGFR,GRB2
721,AIMed.d149,True,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269,Shc,GRB2
722,AIMed.d149,False,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269,IRS-1,EGFR
723,AIMed.d149,False,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269,IRS-1,Shc
724,AIMed.d149,False,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269,EGFR,Shc
725,AIMed.d149,True,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270,GRB2,IRS-1
726,AIMed.d149,True,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270,phosphatidylinositol-3 (PI-3) kinase,IRS-1
727,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270,GRB2,phosphatidylinositol-3 (PI-3) kinase
728,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270,GRB2,IRS-1
729,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270,phosphatidylinositol-3 (PI-3) kinase,IRS-1
730,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270,IRS-1,IRS-1
731,AIMed.d149,True,We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.,AIMed.d149.s1271,GRB2,IRS-1
732,AIMed.d149,True,We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.,AIMed.d149.s1271,GRB2,Shc
733,AIMed.d149,False,We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.,AIMed.d149.s1271,IRS-1,Shc
734,AIMed.d155,False,"The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.",AIMed.d155.s1316,TFIID,TFIID
735,AIMed.d155,False,"The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.",AIMed.d155.s1316,TFIID,TFIID
736,AIMed.d155,False,"The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.",AIMed.d155.s1316,TFIID,TFIID
737,AIMed.d155,False,"Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.",AIMed.d155.s1317,TFIID,TATA binding subunit
738,AIMed.d155,False,"Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.",AIMed.d155.s1317,TFIID,TBP
739,AIMed.d155,False,"Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.",AIMed.d155.s1317,TATA binding subunit,TBP
740,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318,TFIID,hTAF80
741,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318,TFIID,hTAF31
742,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318,TFIID,hTAF20/15
743,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318,hTAF80,hTAF31
744,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318,hTAF80,hTAF20/15
745,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318,hTAF31,hTAF20/15
746,AIMed.d155,False,"Together with analyses of native TFIID complexes and accompanying crystallographic studies, the results suggest that there is a histone octamer-like TAF complex within TFIID.",AIMed.d155.s1319,TFIID,TFIID
747,AIMed.d156,True,IRAK: a kinase associated with the interleukin-1 receptor.,AIMed.d156.s1320,IRAK,interleukin-1 receptor
748,AIMed.d156,True,The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).,AIMed.d156.s1321,interleukin-1,IL-1RI
749,AIMed.d156,True,The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).,AIMed.d156.s1321,IL-1,IL-1RI
750,AIMed.d156,False,The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).,AIMed.d156.s1321,interleukin-1,IL-1
751,AIMed.d156,False,"When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).",AIMed.d156.s1322,IL-1RI,nuclear factor kappa B
752,AIMed.d156,False,"When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).",AIMed.d156.s1322,IL-1RI,NF-kappa B
753,AIMed.d156,False,"When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).",AIMed.d156.s1322,nuclear factor kappa B,NF-kappa B
754,AIMed.d156,False,"A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.",AIMed.d156.s1323,IRAK,IL-1
755,AIMed.d156,False,"A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.",AIMed.d156.s1323,IRAK,IL-1 receptor-associated kinase
756,AIMed.d156,False,"A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.",AIMed.d156.s1323,IL-1,IL-1 receptor-associated kinase
757,AIMed.d156,True,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324,IRAK,IL-1RI
758,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324,IL-1RI,IL-1
759,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324,IL-1RI,IRAK
760,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324,IL-1RI,IL-1RI
761,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324,IL-1,IRAK
762,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324,IL-1,IL-1RI
763,AIMed.d156,False,"The primary amino acid sequence of IRAK shares similarity with that of pelle,a protein kinase that is essential for the activation of a NF-kappa B homolog in Drosophila.",AIMed.d156.s1325,IRAK,NF-kappa B
764,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p22-phox,gp91-phox
765,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p47-phox,p67-phox
766,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p47-phox,cytochrome b558
767,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p67-phox,cytochrome b558
768,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p21rac,cytochrome b558
769,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,NADPH oxidase,cytochrome b558
770,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,NADPH oxidase,p22-phox
771,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,NADPH oxidase,gp91-phox
772,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,NADPH oxidase,p47-phox
773,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,NADPH oxidase,p67-phox
774,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,NADPH oxidase,p21rac
775,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,NADPH oxidase,cytochrome b558
776,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,cytochrome b558,p22-phox
777,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,cytochrome b558,gp91-phox
778,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,cytochrome b558,p47-phox
779,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,cytochrome b558,p67-phox
780,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,cytochrome b558,p21rac
781,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,cytochrome b558,cytochrome b558
782,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p22-phox,p47-phox
783,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p22-phox,p67-phox
784,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p22-phox,p21rac
785,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p22-phox,cytochrome b558
786,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,gp91-phox,p47-phox
787,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,gp91-phox,p67-phox
788,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,gp91-phox,p21rac
789,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,gp91-phox,cytochrome b558
790,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p47-phox,p21rac
791,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438,p67-phox,p21rac
792,AIMed.d170,True,"This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.",AIMed.d170.s1439,p47-phox,p67-phox
793,AIMed.d170,False,"This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.",AIMed.d170.s1439,cytochrome b558,p47-phox
794,AIMed.d170,False,"This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.",AIMed.d170.s1439,cytochrome b558,p67-phox
795,AIMed.d178,True,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508,p27,CDK4
796,AIMed.d178,True,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508,p27,CDK6
797,AIMed.d178,True,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508,p27,CDK2
798,AIMed.d178,False,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508,CDK4,CDK6
799,AIMed.d178,False,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508,CDK4,CDK2
800,AIMed.d178,False,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508,CDK6,CDK2
801,AIMed.d178,False,"Although many different types of proliferating cells contain p27 protein, neither the interactions of p27 with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.",AIMed.d178.s1509,p27,p27
802,AIMed.d178,True,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511,p27,CDK2
803,AIMed.d178,True,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511,p27,CDK4
804,AIMed.d178,True,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511,p27,CDK6
805,AIMed.d178,False,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511,CDK2,CDK4
806,AIMed.d178,False,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511,CDK2,CDK6
807,AIMed.d178,False,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511,CDK4,CDK6
808,AIMed.d178,False,"Furthermore, the amount of p27 is significantly lower than the amount of cyclin D3 in these cells.",AIMed.d178.s1512,p27,cyclin D3
809,AIMed.d178,True,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK4,p27
810,AIMed.d178,True,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK6,p27
811,AIMed.d178,True,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK2,p27
812,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK4,CDK6
813,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK4,CDK2
814,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK4,p27
815,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK6,CDK2
816,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,CDK6,p27
817,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,p27,CDK2
818,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513,p27,p27
819,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516,CDK6,CDK6
820,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516,CDK6,p27
821,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516,CDK6,Rb
822,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516,CDK6,p27
823,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516,CDK6,Rb
824,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516,p27,Rb
825,AIMed.d178,True,"In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.",AIMed.d178.s1517,p27,CDK2
826,AIMed.d178,False,"In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.",AIMed.d178.s1517,p27,histone H1
827,AIMed.d178,False,"In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.",AIMed.d178.s1517,CDK2,histone H1
828,AIMed.d178,False,These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.,AIMed.d178.s1518,cyclin D,CDK2
829,AIMed.d178,False,These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.,AIMed.d178.s1518,cyclin D,p27
830,AIMed.d178,False,These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.,AIMed.d178.s1518,CDK2,p27
831,AIMed.d181,True,Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.,AIMed.d181.s1538,p53,53BP2
832,AIMed.d181,True,The core domain contains the sequence-specific DNA binding activity and the in vitro 53BP2 protein binding activity of p53.,AIMed.d181.s1540,53BP2,p53
833,AIMed.d181,True,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541,p53,53BP2
834,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541,p53,p53
835,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541,p53,p53
836,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541,53BP2,p53
837,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541,53BP2,p53
838,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541,p53,p53
839,AIMed.d181,True,The structure of the complex shows that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding.,AIMed.d181.s1542,53BP2,p53
840,AIMed.d181,True,The six most frequently observed p53 mutations disrupt 53BP2 binding in vitro.,AIMed.d181.s1543,p53,53BP2
841,AIMed.d181,True,The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.,AIMed.d181.s1544,53BP2,p53
842,AIMed.d181,False,The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.,AIMed.d181.s1544,53BP2,p53
843,AIMed.d181,False,The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.,AIMed.d181.s1544,p53,p53
844,AIMed.d186,False,cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.,AIMed.d186.s1579,interleukin 13,interleukin 13 receptor
845,AIMed.d186,False,cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.,AIMed.d186.s1579,interleukin 13,interleukin 13 receptor alpha chain
846,AIMed.d186,False,cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.,AIMed.d186.s1579,interleukin 13 receptor,interleukin 13 receptor alpha chain
847,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580,interleukin 13,interleukin 13 receptor
848,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580,interleukin 13,interleukin 13 receptor alpha chain
849,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580,interleukin 13,IL-13Ralpha
850,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580,interleukin 13 receptor,interleukin 13 receptor alpha chain
851,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580,interleukin 13 receptor,IL-13Ralpha
852,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580,interleukin 13 receptor alpha chain,IL-13Ralpha
853,AIMed.d186,True,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13,IL-13Ralpha
854,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13,IL-13Ralpha
855,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13,IL-4Ralpha
856,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13,IL-13
857,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13,IL-13 receptor
858,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13Ralpha,IL-13Ralpha
859,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13Ralpha,IL-4Ralpha
860,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13Ralpha,IL-13
861,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13Ralpha,IL-13 receptor
862,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13Ralpha,IL-4Ralpha
863,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13Ralpha,IL-13
864,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13Ralpha,IL-13 receptor
865,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-4Ralpha,IL-13
866,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-4Ralpha,IL-13 receptor
867,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582,IL-13,IL-13 receptor
868,AIMed.d186,True,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,IL-13Ralpha,IL-4
869,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,IL-13Ralpha,cytokine receptor gamma chain
870,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,IL-13Ralpha,gammac
871,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,IL-13Ralpha,gammac
872,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,IL-13Ralpha,IL-2
873,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,cytokine receptor gamma chain,gammac
874,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,cytokine receptor gamma chain,IL-4
875,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,cytokine receptor gamma chain,gammac
876,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,cytokine receptor gamma chain,IL-2
877,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,gammac,IL-4
878,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,gammac,gammac
879,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,gammac,IL-2
880,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,IL-4,gammac
881,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,IL-4,IL-2
882,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583,gammac,IL-2
883,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584,IL-13Ralpha,gammac
884,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584,IL-13Ralpha,gammac
885,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584,IL-13Ralpha,IL-13Ralpha
886,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584,gammac,gammac
887,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584,gammac,IL-13Ralpha
888,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584,gammac,IL-13Ralpha
889,AIMed.d188,False,SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.,AIMed.d188.s1595,CREB,CREB-binding protein
890,AIMed.d188,False,"In an unbiased search for potential coactivators of SREBP, we isolated a protein of 265 kD from HeLa cells that directly bound SREBP-1 and SREBP-2.",AIMed.d188.s1598,SREBP-1,SREBP-2
891,AIMed.d188,False,"Peptide sequencing and Western blot analysis established that the 265-kD protein was CBP (CREB-binding protein),a recently identified transcriptional coactivator.",AIMed.d188.s1599,CBP,CREB-binding protein
892,AIMed.d188,False,The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).,AIMed.d188.s1600,CBP,p300
893,AIMed.d188,False,The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).,AIMed.d188.s1600,CBP,CBP
894,AIMed.d188,False,The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).,AIMed.d188.s1600,p300,CBP
895,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,UBE2I,RAD52
896,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,UBE2I,UBL1
897,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,UBE2I,p53
898,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,UBE2I,RAD51
899,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,RAD52,UBL1
900,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,RAD52,p53
901,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,RAD52,RAD51
902,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,UBL1,p53
903,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,UBL1,RAD51
904,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603,p53,RAD51
905,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBE2I,RAD52
906,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBE2I,RAD51
907,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBE2I,p53
908,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBE2I,UBL1
909,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,UBC9
910,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,UBE2I
911,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,RAD52
912,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,RAD51
913,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,p53
914,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,UBL1
915,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBC9,UBE2I
916,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBC9,RAD52
917,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBC9,RAD51
918,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBC9,p53
919,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,UBC9,UBL1
920,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,RAD51
921,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,p53
922,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD52,UBL1
923,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD51,p53
924,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,RAD51,UBL1
925,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606,p53,UBL1
926,AIMed.d189,False,"These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.",AIMed.d189.s1607,UBE2I,RAD6
927,AIMed.d189,False,"These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.",AIMed.d189.s1607,UBE2I,UBC2
928,AIMed.d189,False,"These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.",AIMed.d189.s1607,RAD6,UBC2
929,AIMed.d189,True,The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.,AIMed.d189.s1608,UBE2I,RAD52
930,AIMed.d189,False,The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.,AIMed.d189.s1608,UBE2I,RAD52
931,AIMed.d189,False,The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.,AIMed.d189.s1608,RAD52,RAD52
932,AIMed.d189,False,"These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.",AIMed.d189.s1609,RAD52,p53
933,AIMed.d189,False,"These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.",AIMed.d189.s1609,RAD52,UBE2I
934,AIMed.d189,False,"These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.",AIMed.d189.s1609,p53,UBE2I
935,AIMed.d191,False,"We now find that HIV-1 begins reverse transcription much more efficiently in DCs than T cells, even though T cells have higher levels of CD4 and gp120 binding.",AIMed.d191.s1623,CD4,gp120
936,AIMed.d191,True,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631,RANTES,CCR5
937,AIMed.d191,True,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631,SDF-1,CXCR4
938,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631,RANTES,SDF-1
939,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631,RANTES,CXCR4
940,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631,CCR5,SDF-1
941,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631,CCR5,CXCR4
942,AIMed.d191,False,DCs express more CCR5 and CXCR4 mRNA than T cells.,AIMed.d191.s1633,CCR5,CXCR4
943,AIMed.d200,True,"Using epitope-tagging, interaction of E47 basic-helix-loop-helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells.",AIMed.d200.s1722,E47,eip1
944,AIMed.d200,False,Interactions with human PARP and mouse replication factor 1a were confirmed using glutathione transferase-tagged cDNAs.,AIMed.d200.s1725,PARP,replication factor 1a
945,AIMed.d200,True,A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic-helix-loop-helix only when fused to a beta-galactosidase tag.,AIMed.d200.s1726,nucleolin,E47
946,AIMed.d201,False,Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.,AIMed.d201.s1727,Hepatitis B virus X protein,transcription factor IIB
947,AIMed.d201,False,Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.,AIMed.d201.s1727,Hepatitis B virus X protein,RNA polymerase II subunit 5
948,AIMed.d201,False,Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.,AIMed.d201.s1727,transcription factor IIB,RNA polymerase II subunit 5
949,AIMed.d201,False,Hepatitis B virus X protein (HBx) transactivates viral and cellular genes through a wide variety of cis-elements.,AIMed.d201.s1728,Hepatitis B virus X protei,HBx
950,AIMed.d201,True,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730,HBx,RNA polymerase II subunit 5
951,AIMed.d201,True,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730,HBx,RPB5
952,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730,HBx,HBx
953,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730,RNA polymerase II subunit 5,RPB5
954,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730,RNA polymerase II subunit 5,HBx
955,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730,RPB5,HBx
956,AIMed.d201,False,"In this context, we examined the possibility that HBx and RPB5 interact with other general transcription factors.",AIMed.d201.s1731,HBx,RPB5
957,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732,HBx,RPB5
958,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732,HBx,transcription factor IIB
959,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732,HBx,TFIIB
960,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732,RPB5,transcription factor IIB
961,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732,RPB5,TFIIB
962,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732,transcription factor IIB,TFIIB
963,AIMed.d201,True,"Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.",AIMed.d201.s1733,HBx,RPB5
964,AIMed.d201,False,"Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.",AIMed.d201.s1733,HBx,TFIIB
965,AIMed.d201,False,"Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.",AIMed.d201.s1733,RPB5,TFIIB
966,AIMed.d201,True,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,HBx,RPB5
967,AIMed.d201,True,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,HBx,RPB5
968,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,HBx,TFIIB
969,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,HBx,HBx
970,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,HBx,RPB5
971,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,HBx,TFIIB
972,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,TFIIB,RPB5
973,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,TFIIB,HBx
974,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,TFIIB,RPB5
975,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,TFIIB,TFIIB
976,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,RPB5,HBx
977,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,RPB5,RPB5
978,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,RPB5,TFIIB
979,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,HBx,TFIIB
980,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735,RPB5,TFIIB
981,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736,HBx,TFIIB
982,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736,HBx,RPB5
983,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736,HBx,TFIIB
984,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736,TFIIB,RPB5
985,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736,TFIIB,TFIIB
986,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736,RPB5,TFIIB
987,AIMed.d203,False,A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist.,AIMed.d203.s1746,IL-1,IL-1 receptor
988,AIMed.d203,False,"Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).",AIMed.d203.s1747,interleukin-1,IL-1
989,AIMed.d203,False,"Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).",AIMed.d203.s1747,interleukin-1,tumour necrosis factor-alpha
990,AIMed.d203,False,"Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).",AIMed.d203.s1747,IL-1,tumour necrosis factor-alpha
991,AIMed.d203,True,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1 receptor,IL-1alpha
992,AIMed.d203,True,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL1R,IL-1beta
993,AIMed.d203,True,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1-receptor,IL1RA
994,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1 receptor
995,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL1R
996,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1alpha
997,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1beta
998,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1
999,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1-receptor
1000,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1-receptor antagonist
1001,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL1RA
1002,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1 receptor,IL1R
1003,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1 receptor,IL-1beta
1004,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1 receptor,IL-1
1005,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1 receptor,IL-1-receptor
1006,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1 receptor,IL-1-receptor antagonist
1007,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1 receptor,IL1RA
1008,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL1R,IL-1alpha
1009,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL1R,IL-1
1010,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL1R,IL-1-receptor
1011,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL1R,IL-1-receptor antagonist
1012,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL1R,IL1RA
1013,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1alpha,IL-1beta
1014,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1alpha,IL-1
1015,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1alpha,IL-1-receptor
1016,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1alpha,IL-1-receptor antagonist
1017,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1alpha,IL1RA
1018,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1beta,IL-1
1019,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1beta,IL-1-receptor
1020,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1beta,IL-1-receptor antagonist
1021,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1beta,IL1RA
1022,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1-receptor
1023,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL-1-receptor antagonist
1024,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1,IL1RA
1025,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1-receptor,IL-1-receptor antagonist
1026,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748,IL-1-receptor antagonist,IL1RA
1027,AIMed.d203,True,Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.,AIMed.d203.s1750,type-I IL1R,IL1RA
1028,AIMed.d203,False,Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.,AIMed.d203.s1750,IL1R,type-I IL1R
1029,AIMed.d203,False,Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.,AIMed.d203.s1750,IL1R,IL1RA
1030,AIMed.d203,False,"A region that is important for biological function in IL-1beta, the 'receptor trigger site' is not in direct contact with the receptor in the IL1RA complex.",AIMed.d203.s1754,IL-1beta,IL1RA
1031,AIMed.d210,True,Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.,AIMed.d210.s1817,USF,Fra1
1032,AIMed.d210,False,Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.,AIMed.d210.s1817,USF,AP1
1033,AIMed.d210,False,Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.,AIMed.d210.s1817,Fra1,AP1
1034,AIMed.d210,False,"To further examine the function of the bHLHZip protein, USF, we screened for cellular proteins which could directly interact with USF using the yeast two-hybrid system.",AIMed.d210.s1819,USF,USF
1035,AIMed.d210,True,"A bZip protein, Fra1, was found to efficiently interact with USF.",AIMed.d210.s1820,Fra1,USF
1036,AIMed.d210,True,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,USF,Fra1
1037,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,USF,c-Fos
1038,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,USF,Fra2
1039,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,USF,FosB
1040,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,USF,c-Jun
1041,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,Fra1,c-Fos
1042,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,Fra1,Fra2
1043,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,Fra1,FosB
1044,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,Fra1,c-Jun
1045,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,c-Fos,Fra2
1046,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,c-Fos,FosB
1047,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,c-Fos,c-Jun
1048,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,Fra2,FosB
1049,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,Fra2,c-Jun
1050,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821,FosB,c-Jun
1051,AIMed.d210,True,Both the bHLHZip and the N-terminal regions of Fra1 are required for efficient interaction with USF.,AIMed.d210.s1822,Fra1,USF
1052,AIMed.d210,True,In vivo association between USF and Fra1 has been demonstrated by co-immunoprecipitation.,AIMed.d210.s1823,USF,Fra1
1053,AIMed.d210,False,Expression of exogenous USF led to a decrease in AP1-dependent transcription in F9 cells.,AIMed.d210.s1824,USF,AP1
1054,AIMed.d210,False,Co-expression of exogenous Fra1 restored the AP1 activity in a dose-dependent manner.,AIMed.d210.s1825,Fra1,AP1
1055,AIMed.d210,True,These data show that USF and Fra1 physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.,AIMed.d210.s1826,USF,Fra1
1056,AIMed.d212,True,Interaction between ATM protein and c-Abl in response to DNA damage.,AIMed.d212.s1835,ATM,c-Abl
1057,AIMed.d212,False,"The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated ATM (for 'AT mutated'), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response.",AIMed.d212.s1836,ATM,AT mutated
1058,AIMed.d212,True,"Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.",AIMed.d212.s1838,ATM,c-Abl
1059,AIMed.d212,False,"Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.",AIMed.d212.s1838,c-Abl,ATM
1060,AIMed.d212,False,"Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.",AIMed.d212.s1838,c-Abl,c-Abl
1061,AIMed.d212,True,Here we show that ATM binds c-Abl constitutively in control cells but not in AT cells.,AIMed.d212.s1839,ATM,c-Abl
1062,AIMed.d212,True,"Our results demonstrate that the SH3 domain of c-Abl interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of ATM.",AIMed.d212.s1840,c-Abl,ATM
1063,AIMed.d212,True,These findings indicate that ATM is involved in the activation of c-Abl by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.,AIMed.d212.s1842,ATM,c-Abl
1064,AIMed.d221,True,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921,interferon alpha receptor,Jak1
1065,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921,interferon alpha,interferon alpha receptor
1066,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921,interferon alpha,Jak1
1067,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921,interferon alpha,Jak
1068,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921,interferon alpha receptor,Jak
1069,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921,Jak1,Jak
1070,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922,interferon alpha,IFNalpha
1071,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922,interferon alpha,interferon alpha (IFNalpha) receptor
1072,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922,interferon alpha,IFNalpha
1073,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922,IFNalpha,interferon alpha (IFNalpha) receptor
1074,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922,IFNalpha,IFNalpha
1075,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922,interferon alpha (IFNalpha) receptor,IFNalpha
1076,AIMed.d221,False,Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the betaL chain are sufficient to activate the Jak-Stat pathway and trigger an antiviral state after IFNalpha2 binding to the receptor.,AIMed.d221.s1924,Jak,IFNalpha2
1077,AIMed.d221,False,"This region of the betaL chain, required for Jak1 binding and activation, contains the Box 1 motif that is important for the interaction of some cytokine receptors with Jak kinases.",AIMed.d221.s1925,Jak1,Jak
1078,AIMed.d223,True,"Interaction between cell cycle regulator, E2F-1, and NF-kappaB mediates repression of HIV-1 gene transcription.",AIMed.d223.s1934,E2F-1,NF-kappaB
1079,AIMed.d223,False,The NF-kappaB/Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression.,AIMed.d223.s1935,NF-kappaB,Rel
1080,AIMed.d223,True,Some of these extracellular stimuli arrest cells in the G1 phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein Rb and its partner E2F-1.,AIMed.d223.s1936,Rb,E2F-1
1081,AIMed.d223,True,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938,E2F-1,NF-kappaB
1082,AIMed.d223,True,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938,E2F-1,p50
1083,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938,E2F-1,NF-kappaB
1084,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938,NF-kappaB,NF-kappaB
1085,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938,NF-kappaB,p50
1086,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938,NF-kappaB,p50
1087,AIMed.d223,False,Gel retardation and methylation interference assays show that E2F-1 is able to bind specifically to a site embedded within the two NF-kappaB elements.,AIMed.d223.s1939,E2F-1,NF-kappaB
1088,AIMed.d223,False,Gel retardation/immunoblot analysis using purified E2F-1 and p50 homodimers reveals the presence of complexes containing both proteins.,AIMed.d223.s1940,E2F-1,p50
1089,AIMed.d223,True,Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of E2F-1 and p50 in the absence of their DNA target sequences.,AIMed.d223.s1941,E2F-1,p50
1090,AIMed.d223,False,In vitro transcription assay demonstrates that E2F-1 represses NF-kappaB mediated transcription in a cell-free system.,AIMed.d223.s1942,E2F-1,NF-kappaB
1091,AIMed.d223,False,"Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.",AIMed.d223.s1943,E2F,NF-kappaB
1092,AIMed.d223,False,"Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.",AIMed.d223.s1943,E2F,E2F-1
1093,AIMed.d223,False,"Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.",AIMed.d223.s1943,NF-kappaB,E2F-1
1094,AIMed.d223,True,"The results of this study suggest that NF-kappaB activity may be regulated by its interaction with the cell cycle regulatory protein, E2F-1.",AIMed.d223.s1944,NF-kappaB,E2F-1
